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Objectives: Succinic acid as endogenous metabolite, has a wide range of applica-
tions in medical care. We conduct research on the development of new medicines 
based on succinic acid, ascorbic acid and rutin for the prevention and treatment of 
influenza. A systematic review was carried out to perform a qualitative assessment 
of succinic acid adding in the various medicines and to determine of their phar-
macological action. MethOds: MEDLINE®, EMBASE®, Scopus, Cochrane Library 
databases and clinical trials registers between 1966 and Jun 2015 were performed. 
To analyze the RCT were selected and Review on the Study of the pharmacological 
action of drugs, which include succinic acid. Quality of evidence was assessed and 
each article was rated of quality. Results: Our study included 29 articles (23 RCT 
and 6 Review). The evidence varied in terms of: scope and years of research, type 
of treatment, study duration, sample size (< 100 to> 500 patients). Generally, the 
mean age of included patients was middle. For pharmacological properties and by 
relevance RCT are grouped as follows: antigypoxic action were 7 RCT (2003-2013 
years), improve iron absorption in the gastrointestinal tract - 6 RCT (1966-1974), 
hepatoprotective - 4 RCT (2013-2014 years). One RCT proves the efficiency of suc-
cinic acid used in gastroenterology (a combination with omeprazole, 2012), depres-
sion (2013), in transplantation (1993) at menopause (2008), renal failure (2013), to 
improve body temperature during surgery (2007). Analysis of Review opens the new 
prospects for the use of succinic acid in cancer, diabetes and hepatitis C treat-
ment. cOnclusiOns: A comprehencive overview of these studies estimated the 
evidence of succinic acid addition of the drugs. Succinic acid as endogenous metabo-
lite, is a part of drugs of different pharmacological actions. These clinical trial results 
have been retrieved and give the possibility to develop of new drugs with succinic 
acid also in Ukraine.
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bAckgROund: The Parkinson’s Kinetigraph (PKG) is the first device that objec-
tively measures treatable Parkinson’s Disease (PD) symptoms in daily living. 
Collected symptom scores – Bradykinesia [BKS], Dyskinesia [DKS], and Fluctuation 
[FDS] – have been validated and correlate with PD reference standard instru-
ments (UPDRS, AIMS, Patient Diaries). The PKG is used globally – in Europe, 
Asia-Pacific, and the USA. There is a de-identified central repository of all PKG 
reports. Objectives: Using the central repository, to assess whether patients 
who received a PKG analysis in routine care featured improved PD symptom scores 
over time. MethOds: PD patients who had 2+ PKGs within a 6-month time frame 
were eligible for analysis. A total of 591 patients were included and split into 
“controlled” and “uncontrolled” at baseline (first PKG), based on pre-defined cut-
off scores for BKS (23) or DKS (5); for FDS, a normal range was defined, above and 
below which patients were considered uncontrolled. The Mann-Whitey U test 
was used for analysis. Results: For those patients featuring scores considered 
“uncontrolled” (BKS high, DKS high, FDS low or high) at baseline, a statistically and 
clinically significant improvement, on average, was recorded for that score in their 
second PKG in all 4 subgroups (p< 0.01). For those patients with uncontrolled FDS 
at baseline, 43% (FDS low) and 34% (FDS high) had scores considered controlled 
in their second PKG; regarding high DKS, 69% showed some improvement. All 
improved scores were sustained or somewhat augmented on average in those 
patients having more than 2 PKGs. cOnclusiOns: The analysis suggests that 
adding a PKG to a PD patient’s therapy management may significantly improve, 
and subsequently sustain, patient PD scores over time. This is important as, due 
to natural PD progression, one would expect PKG symptom scores to deteriorate 
over time. Other potential PKG benefits were not part of this analysis.
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Objectives: Spasticity is one of the well-recognized complications of stroke which 
may give rise to pain and limit patients’ ability to perform daily activities. The pre-
disposing factors and direct effects of post-stroke spasticity (PSS) also involve high 
management costs in terms of healthcare resources and case-control designs are 
required for establishing such differences. In ‘The Health Improvement Network’ 
(THIN) database, such a study was difficult to provide reliable estimates since the 
prevalence of post-stroke spasticity was found to be substantially below the most 
conservative previously reported estimates. The objective of this study was to use 
predictive analysis techniques to determine if there were a substantial number of 
potentially under-recorded patients with PSS. MethOds: This study used retrospec-
tive data from adult patients with a diagnostic code for stroke between 2007 and 
2011 registered in THIN. Two algorithm approaches were developed: 1) a statistically 
validated data-trained algorithm using machine techniques and 82 potential predic-
tors; and 2) a clinician-trained algorithm based on the review of 200 stroke cases 
by two expert neurologists. The algorithm with the better performance was used 
to identify PSS cases. Results: In THIN data, 45,613 stroke events were identified, 
with 660 having a diagnosis PSS. A data-trained algorithm using Random Forest 
showed better prediction performance than the clinician-trained algorithm, with 
higher sensitivity and only marginally lower specificity. Overall accuracy was 84% 
and 72%, respectively. The data-trained algorithm predicted an additional 3,912 
records consistent with patients developing spasticity in the 12 months following a 
stroke. cOnclusiOns: Using machine learning techniques, additional unrecorded 
post-stroke spasticity patients were identified, increasing the condition’s prevalence 
was the primary endpoint, and compared the assessments. Results: Guidance from 
regulatory and HTA agencies indicates the suitability of PFS as an endpoint depends 
on the cancer type and stage, seen in assessments of afatinib and erlotinib in non-
small cell lung cancer and bevacizumab in ovarian cancer: FDA and EMA approvals 
were based on PFS data. However, the TC in France awarded ASMR IV for erlotinib and 
bevacizumab and ASMR V for afatinib. NICE in the UK approved afatinib and erlotinib 
based on additional interim OS data and a patient access scheme; bevacizumab was 
not approved because of uncertainty in translating PFS gain to OS. cOnclusiOns: 
PFS is a valid and credible endpoint in many oncology trials. However, differences 
in stakeholder perspectives and evidentiary requirements may mean that products 
approved on the basis of PFS data face delays in HTA or protracted pricing negotia-
tions, or are rejected for reimbursement. PFS as an endpoint allows shorter trials , 
efficiency is improved, and fewer patients are exposed to an investigational drug. 
The limitations associated with PFS as an endpoint are largely manageable. Thus, the 
value and relevance of PFS needs to be recognized consistently across HTA agencies, 
and approaches harmonized between HTA agencies and regulators.
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Objectives: To elicit a comprehensive stakeholder view on the acceptability of using 
real-world evidence (RWE) for informing trial design and establishing relative effec-
tiveness (RE) of new medicines in regulatory and HTA assessments. MethOds: IMI 
GetReal (www.imi-getreal.eu) is facilitating stakeholder dialogue on the role of RWE 
through case studies which focus on RE issues in several disease areas. In a series of 
pilot workshops, stakeholders considered challenges in establishing the RE of multiple 
sclerosis (MS) medicines. Alternative solutions were proposed for using RWE to miti-
gate these challenges: participants provided views on the usefulness and acceptability 
of solutions and the potential impact on regulatory and reimbursement decision 
making. Results: Three approaches were proposed: 1) supplementing trial results 
with RWE in network meta-analysis (NMA) to generate RE estimates; 2) incorporating 
RWE in NMA to support simulations informing trial designs; 3) using risk equations 
derived from RWE to inform risk stratified trial designs. Stakeholders cautiously wel-
comed the proposals as additional options for reducing decision-making uncertainty, 
raising the key issue of potential biases that could be introduced by including RWE in 
these ways. The inclusion of RWE would most likely be considered as supportive of or 
adding context to regulatory submissions, but could be more central in HTA decision 
making and early medicine development if appropriate quality control measures 
are put in place to mitigate biases commonly associated with non-interventional 
data. cOnclusiOns: For the use of RWE to become more acceptable by decision mak-
ers, standard methods for data synthesis should be developed, as well as guidelines 
to ensure transparency in selection of data sources and data synthesis. The GetReal 
consortium provides a ‘safe harbour’ for stakeholders to discuss the potential use of 
RWE for decision making, and further work is ongoing to develop methods for the 
‘early’ use of RWE and to foster dialogue between stakeholders.
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Objectives: Objective of this study was to provide a baseline against which 
to monitor trends in breast cancer awareness and the effect of interventions to 
promote breast cancer awareness. MethOds: A cross sectional house hold survey 
was conducted on 365 young women between the age group of 18-40 in urban and 
rural areas of South India using a validated questionnaire. Results: A total of 99% 
respondents knew that breast cancer is the leading cancer with a mean knowl-
edge of 73.7±15.1% for urban and 47.2±13.9% for rural women. Sources of infor-
mation for their knowledge were mainly health professionals/workers (98.2%), 
friends/neighbors (83.5%), TV/Radio (76.0%) and printed materials (60.2%). Rural 
women had significantly less awareness compared to urban women. Majority 
of the respondents knew the risk factors of breast cancer aging (69%), nullipar-
ity (56.4%), delivery at more than 30 years old (46%), shorter duration of breast 
feeding (72.0%), contraceptive pills (46.0%), obesity (80.0%), big breast (81%), hor-
mone replacement therapy (HRT) (54.4%), menopause after the age of 50 (20%) and 
menarche before age 11(34.8%). most of the respondents agreed that the following 
are risk factors smoking (85.2%), alcohol intake (86.8%) and exposure to radiation 
(67.2%).the rural respondents strongly believed that breast cancer with wearing 
of underwire bra (34.3%) but most of the urban respondents not believed (65.6%).
Regarding awareness of the screening methods, 66% and 49% were aware about 
BSE and CBE respectively, 78% were aware about mammography. cOnclusiOns: 
The study showed awareness of breast cancer and practice of screening procedures 
increases with higher education and urban living. Therefore, there is an urgent 
need to conduct breast cancer awareness camps in rural areas for an intensive 
breast cancer awareness campaign and availability of screening centers prioritized 
in rural areas.
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be investigated by pooling RCT and RWE data in a response surface analysis. The 
maximum effect may be established in a region of treatment/dose combination 
not yet studied in a randomised setting. This methodology can also be used to 
determine which combination of patient’s characteristics will result in the most 
optimal effect for each (line) of therapy and as a result, provide targeted treatment 
for (groups of) patients based on their baseline characteristics. Further work could 
involve optimizing the response in higher dimensions.
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Objectives: To determine which clinical outcomes, both “soft” and “hard”, are cur-
rently used in phase III treatment studies for hematoncologic diseases, and what 
proportion of them use overall survival (OS) as the primary outcome. MethOds: 
Through a search in PubMed, we identified and analyzed all randomized clinical 
trials published in the last 10 years, for de novo treatments in adults. Results: 
The initial search yielded 310 references, from which 90 trials were selected. The 
most studied disease was multiple myeloma, with 29 studies, followed by non-
Hodgkin lymphoma with 26. The others were acute myeloid leukemia 12, chronic 
lymphocytic leukemia 10, chronic myeloid leukemia 8, myelodysplastic syndromes 
3 and Hodgkin lymphoma 2. The 90 studies had a total of 108 “primary” and 252 
“secondary” outcomes; 20 studies (22%) had OS as primary endpoint (though only 
3 of them reached statistical significance), in over 37 (41%) OS was grouped with 
other outcomes to form a composite endpoint. In 55 studies (61%) overall survival 
was a secondary outcome. Quality of life was a “secondary” outcome in 10 stud-
ies. cOnclusiOns: Although OS is the gold standard in cancer therapy, grouped 
outcomes, or others intermediate outcomes, such as progression-free survival or 
paraclinical indicators of disease activity are more frequently used and may be good 
predictors. Intermediate outcomes require smaller sample sizes and less follow-up. 
Their capacity to predict OS (or, indeed, quality of life) should be carefully assessed. 
Only in the most aggressive forms of cancer is routine use of OS survival justified 
as the primary endpoint.
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Objectives: The objectives of this study were: 1) to compare low back pain (LBP) 
patient valuations with those of the general population, 2) to explore how various 
aspects of health-related quality of life as measured by the EQ-5D-3L impact LBP 
patient valuations, and 3) to explore the implications of the choice of valuation 
method for cost-utility analyses (CUAs). MethOds: Data of 483 LBP patients who 
participated in a 52-week Dutch randomized controlled trial were used. Outcome 
measures included the EQ-5D-3L, EQ-VAS, and societal costs. Patient valuations were 
derived from the EQ-VAS. Population valuations were derived using a Dutch VAS-
based EQ-5D-3L value set. The difference and agreement between both valuations 
were assessed using t-tests and intraclass correlation coefficients (ICC), respectively. 
An ordinary least square linear regression model was constructed to explore how 
various aspects of health-related quality of life as measured by the ED-5D-3L impact 
LBP patient valuations. Moreover, two CUAs were performed; one using patient 
valuations and one using population valuations. Results: Patients valued their 
health state 0.098 (95%CI: 0.082 to 0.115) points higher compared with the general 
population. The two valuations had an ICC of 0.544. The regression model indicated 
that 22.2% of the variance in patient valuations was explained by the LBP patients’ 
EQ-5D-3L health state (R2= 0.222), and that LBP patients gave the most weight to 
the anxiety/depression dimension. In the CUA, the maximum probability of cost-
effectiveness was found to be lower when patient (i.e. 0.28) instead of population 
valuations (i.e. 0.38) were used. cOnclusiOns: This study demonstrated that LBP 
patients value their health state higher than members of the general population and 
that the choice of valuation method could have important implications for CUAs. As 
consensus does currently not exist regarding the question of ‘whose values count’, 
researchers are encouraged to explore these implications using sensitivity analyses.
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Objectives: Stochastic multicriteria acceptability analysis (SMAA) is a power-
ful tool for health technology benefit-risk assessment when health outcomes are 
assessed according to multicriteria and both the outcomes and preference weights 
are subject to uncertainty, in particular with missing weight information. We pro-
pose using a Bayesian approach for SMAA to provide an alternative or supplement 
to the standard SMAA. It can estimate the posterior distributions of decision maker’s 
preference weights on multicriteria, had he/she prefer treatment A over B. Given 
the preference on previous treatments and safety and efficacy profiles, it can also 
predict the decision maker’s preference on a new treatment. MethOds: The SMAA 
method was adapted to fit into the Bayesian framework, assuming that the weights 
follow a Dirichlet prior distribution. A simple Monte-Carlo procedure was developed 
to calculate the posterior distribution for the weights, and Bayesian estimates of 
major measures in standard SMAA were derived. An algorithm was also developed 
to predict future rankings. The method allows using informative, non-informative 
or hierarchical priors, and can be extended to other SMAA methods such as that 
based the prospect theory (SMAA-P). This method is applied to the assessment of 
in THIN from 2% to 13%. This work shows the potential for under-reporting of PSS 
in primary care data, and provides a method for improved identification of cases 
and control records for future studies.
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Objectives: The therapeutic options for Multiple Sclerosis(MS) improved over the 
past years with the approval of new substances. Therapeutic optimization must take 
into account an individualized assessment of clinical and imaging disease activity, 
treatment response as well as identifying early risk factors for treatment failure. 
This study will address by assess this issue by 1. Assess the utility of a tool that 
helps to identify patients with ongoing disease activity 2. The systematic collection 
of a broader set of functional domains to explore their potential to be used as a 
predictive measure of future disease activity or treatment response. 3. Evaluate the 
clinical course of patients according to NEDA-4 parameter as measured by relapse 
activity, disability progression, MRI activity and change in brain volume. 4. Assess 
the therapeutic effectiveness of switching to fingolimod if the patients are assessed 
to be failing their current first line therapy. MethOds: 1500 patients are planned to 
be included in this observational study. All patients with active disease as defined by 
Lublin et al., 2014, undergo a first evaluation of the patient status. Patients switching 
to fingolimod are followed for 3 years. The study set up and documentation param-
eters are based on three bullets: 1. Optimal patient management in daily clinical 
practice using the patient management system MSDS3D 2. State of the art evalua-
tion of the patient status using the MS-disease activity measurement tool 3. Multiple 
sclerosis optimized MRI-acquisition and analysis by central MRI-reading Results: 
and cOnclusiOns: PANGAEA 2.0 will give important insights on the predictive 
value of proposed treatment algorithms like the Lublin criteria and the modified Rio 
Score as well as the principle of NEDA (no evidence of disease activity) -4. It will also 
evaluate the benefit of a collection of a broad range of outcome parameter based on 
functional domains from a patient and physician perspective on therapy decisions.
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Objectives: Syntheses of time-to-event data often rely on published hazard 
ratios (HR) therefore assuming proportional hazards (PH). Methods now exist to 
reconstruct individual patient data (IPD) from published Kaplan-Meier (KM) plots. 
This enables the PH assumption to be formally tested, and a time ratio (TR) to 
be estimated as an alternative measure of relative treatment effect. While TRs do 
not require the PH assumption, these are rarely used in evidence synthesis. We 
compared TRs with HRs to demonstrate their ease of interpretation and transpar-
ency. MethOds: Relative treatment effect measures HRs and TRs were compared 
in terms of: scale, underlying assumptions, interpretation, availability in published 
literature and derivation. Results: HRs act on the log-hazard scale representing 
the ratio of hazards for treatment vs. control. TRs act on the log-failure time scale, 
representing the ratio of failure times for treatment vs. control. A HR< 1 represents 
a decrease in the event hazard whilst a TR< 1 represents an acceleration in time-
to-event, with treatment. The inverse of the TR, referred to as the acceleration fac-
tor (AF), therefore represents the same direction of benefit as for HRs. For TR= 2, 
AF= 0.5, the time-to-event for treatment is two times that for control. HRs are com-
monly reported to summarise the average relative treatment effect. TRs are rarely 
reported and hence less familiar to clinicians, but can be validated against any ratio 
of published survival times. cOnclusiOns: Relative treatment effects expressed 
as TRs are not commonly utilised in evidence synthesis due to unfamiliarity around 
interpretation and lack of availability in the published literature. When converted 
to AFs, TRs have a similar interpretation to HRs and can be estimated from IPD and 
published KM data. Therefore, evidence synthesis should no longer rely on published 
HRs as the measure of relative treatment effect when the PH assumption is violated.
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Objectives: Due to high costs, randomised clinical trials (RCTs) typically do not 
include a wide variety of doses and treatments within a single trial. Real-world 
evidence (RWE) can be used to fill the gaps left by treatment arms or doses not 
studied in first or second line RCTs. This is illustrated in rheumatoid arthritis (RA). 
The combined evidence can allow for investigating the area of dosing that can only 
be studied when all evidence is included. This may impact future dosing strategies 
that could result in approval of treatment (combinations) that may not have been 
studied otherwise but could substantially benefit patients with RA. MethOds: 
RCT and RWE data was combined in a network meta-analysis (NMA) to investigate 
treatment effects in patients with RA. Response surface methods were used to 
investigate the three dimensional surface of the observed effects as a function of 
doses for each pair of treatments. Optimization methods were used to establish the 
optimal treatment/dose region in patients with RA. Results: Results showed that 
including RWE has increased the totality of evidence with reduced uncertainty in 
first and second line treatment effects in patients with RA. The greatest evidence 
of effect was observed in a treatment/dose combination region not yet studied in 
RCTs cOnclusiOns: The optimal treatment regimen for patients with RA can 
